{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:53:42Z","timestamp":1791928422202,"version":"4.3.4"},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:p>The international community has committed to end the tuberculosis (TB) epidemic by 2030. To facilitate the meeting of the global incidence and mortality indicators set by the World Health Organization's End TB Strategy, the Stop TB Partnership launched the three 90-(90)-90 diagnostic\n and treatment targets in 2014. In this paper, we argue that a \u2018fourth 90\u2019\u2014Ensuring that 90% of all people successfully completing treatment for TB can have a good health-related quality of life'\u2014should be considered. Many individuals who successfully complete anti-TB\n treatment are burdened with lifelong comorbidities\u2014human immunodeficiency virus (HIV) and diabetes mellitus, obstructive and restrictive lung disease, involving lung destruction, cavitation, fibrosis and bronchiectasis, that either pre-existed or developed as a result of TB (e.g., chronic\n pulmonary aspergillosis), permanent disabilities such as hearing loss resulting from second-line anti-TB drugs, and mental health disorders. These need to be identified during TB treatment and appropriate care and support provided after anti-TB treatment is successfully completed. A \u2018fourth\n 90\u2019 has also been proposed for the UNAIDS 90-90-90 targets similar in scope to what is being suggested here for TB. Adoption by both HIV and TB control programmes would highlight the current focus on integrated person- and family-centred services.<\/jats:p>","DOI":"10.5588\/ijtld.19.0471","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T01:06:02Z","timestamp":1574384762000},"page":"1253-1256","source":"Crossref","is-referenced-by-count":33,"title":["Should we consider a \u2018fourth 90\u2019 for tuberculosis?"],"prefix":"10.5588","volume":"23","author":[{"given":"A. D.","family":"Harries","sequence":"first","affiliation":[{"name":"International Union Against Tuberculosis and Lung Disease, Paris, France, Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A.","family":"Dlodlo","sequence":"additional","affiliation":[{"name":"International Union Against Tuberculosis and Lung Disease, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Brigden","sequence":"additional","affiliation":[{"name":"International Union Against Tuberculosis and Lung Disease, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mortimer","sequence":"additional","affiliation":[{"name":"International Union Against Tuberculosis and Lung Disease, Paris, France, Liverpool School of Tropical Medicine, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Jensen","sequence":"additional","affiliation":[{"name":"International Union Against Tuberculosis and Lung Disease, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. I.","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"International Union Against Tuberculosis and Lung Disease, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Castro","sequence":"additional","affiliation":[{"name":"International Union Against Tuberculosis and Lung Disease, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Chakaya","sequence":"additional","affiliation":[{"name":"International Union Against Tuberculosis and Lung Disease, Paris, France, Department of Medicine, Therapeutics, Dermatology and Psychiatry, Kenyatta University, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2019\/00000023\/00000012\/art00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T04:33:38Z","timestamp":1615437218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.19.0471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":0,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12,1]]}},"alternative-id":["1027-3719(20191201)23:12L.1253;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.19.0471","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,1]]}}}